< 1 minute read
Oct. 6, 2021

BAY-8400: An Oral Selective DNA-PK Kinase Inhibitor

BAY-8400

oral selective DNA-PK kinase inhibitor synergy with radiotherapy in model from library screen Journal of Medicinal Chemistry Bayer AG, Berlin, Germany

drughunter.com
Drug Hunter Team

The Bayer DNA-PK inhibitor, BAY-8400 , is an orally active and selective DNA-PK kinase inhibitor that synergistically enhances the efficacy of radiotherapeutics in xenograft models. The program started with a campaign to identify ATR inhibitors, which resulted in hits against ATR, ATM, and DNA-PK, all of which are of interest due to their [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in